Merck Property, Plant, and Equipment 2012-2026 | MRK
Merck property, plant, and equipment from 2012 to 2026. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
- Merck property, plant, and equipment for the quarter ending March 31, 2026 was $25.639B, a 9.35% increase year-over-year.
- Merck property, plant, and equipment for 2024 was $23.779B, a 3.16% increase from 2023.
- Merck property, plant, and equipment for 2023 was $23.051B, a 7.6% increase from 2022.
- Merck property, plant, and equipment for 2022 was $21.422B, a 11.12% increase from 2021.
|
Merck Annual Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2024 | $23,779 |
| 2023 | $23,051 |
| 2022 | $21,422 |
| 2021 | $19,279 |
| 2020 | $17,000 |
| 2019 | $15,053 |
| 2018 | $13,291 |
| 2017 | $12,439 |
| 2016 | $12,026 |
| 2015 | $12,507 |
| 2014 | $13,136 |
| 2013 | $14,973 |
| 2012 | $16,030 |
| 2011 | $16,297 |
|
Merck Quarterly Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2025-09-30 | $25,639 |
| 2025-06-30 | $25,236 |
| 2025-03-31 | $24,793 |
| 2024-12-31 | $23,779 |
| 2024-09-30 | $23,446 |
| 2024-06-30 | $23,221 |
| 2024-03-31 | $23,045 |
| 2023-12-31 | $23,051 |
| 2023-09-30 | $22,526 |
| 2023-06-30 | $22,231 |
| 2023-03-31 | $21,758 |
| 2022-12-31 | $21,422 |
| 2022-09-30 | $20,424 |
| 2022-06-30 | $20,059 |
| 2022-03-31 | $19,747 |
| 2021-12-31 | $19,279 |
| 2021-09-30 | $18,565 |
| 2021-06-30 | $18,064 |
| 2021-03-31 | $18,295 |
| 2020-12-31 | $17,000 |
| 2020-09-30 | $16,919 |
| 2020-06-30 | $15,789 |
| 2020-03-31 | $15,269 |
| 2019-12-31 | $15,053 |
| 2019-09-30 | $14,287 |
| 2019-06-30 | $13,862 |
| 2019-03-31 | $13,506 |
| 2018-12-31 | $13,291 |
| 2018-09-30 | $12,755 |
| 2018-06-30 | $12,626 |
| 2018-03-31 | $12,561 |
| 2017-12-31 | $12,439 |
| 2017-09-30 | $12,189 |
| 2017-06-30 | $12,094 |
| 2017-03-31 | $12,042 |
| 2016-12-31 | $12,026 |
| 2016-09-30 | $12,029 |
| 2016-06-30 | $11,987 |
| 2016-03-31 | $12,360 |
| 2015-12-31 | $12,507 |
| 2015-09-30 | $12,482 |
| 2015-06-30 | $12,630 |
| 2015-03-31 | $12,910 |
| 2014-12-31 | $13,136 |
| 2014-09-30 | $13,438 |
| 2014-06-30 | $13,893 |
| 2014-03-31 | $14,296 |
| 2013-12-31 | $14,973 |
| 2013-09-30 | $15,323 |
| 2013-06-30 | $15,683 |
| 2013-03-31 | $15,802 |
| 2012-12-31 | $16,030 |
| 2012-09-30 | $15,884 |
| 2012-06-30 | $15,867 |
| 2012-03-31 | $16,124 |
| 2011-12-31 | $16,297 |
| 2011-09-30 | $16,383 |
| 2011-06-30 | $16,671 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |